Drug Type Antibody drug conjugate (ADC) |
Synonyms GENA-111-auristatin F |
Target |
Action inhibitors |
Mechanism BCAM inhibitors(basal cell adhesion molecule (Lutheran blood group) inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Skin Neoplasms | Preclinical | South Korea | 15 Jun 2022 | |
| Skin Neoplasms | Preclinical | Switzerland | 15 Jun 2022 | |
| Skin Neoplasms | Preclinical | Switzerland | 15 Jun 2022 | |
| Neoplasms | Preclinical | South Korea | 11 Apr 2022 | |
| Squamous Cell Carcinoma | Preclinical | South Korea | 11 Apr 2022 | |
| Squamous Cell Carcinoma | Preclinical | Switzerland | 11 Apr 2022 |






